Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amylmetacresol is a phenolic antiseptic used primarily in over-the-counter lozenges for the treatment of sore throat and minor mouth and throat infections, including pharyngitis and gingivitis. It is commonly formulated with dichlorobenzyl alcohol (as in Strepsils) to provide synergistic antibacterial action. Amylmetacresol exhibits antibacterial, antiviral, antifungal, and mild local anesthetic properties. Its mechanism of action includes denaturation of external protein spikes on pathogens, pH-induced rearrangement of viral attachment proteins, selective effects on viral lipid membranes/protein–lipid interactions, and reversible blockade of voltage-gated sodium channels (notably sodium channel protein type 2 subunit alpha), similar to local anesthetics. The drug is rapidly absorbed when administered orally as a lozenge and quickly eliminated via the kidneys after metabolism[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amylmetacresol.